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MAN MADE ORGANS: TECHNOLOGY MADE IT POSSIBLE
BUT CAN THE FDA KEEP UP?
AMANDA CHATMAN
INTRODUCTION
A transplant surgeon has five patients that each need a different organ to
survive. There are no organs available to perform any of these five transplant operations. A healthy young man comes in for a routine checkup. In
the course of doing the checkup, the doctor discovers that his organs are
compatible with all five of his dying patients. Suppose further that the
young man has no family members or friends and would not be missed if he
were to disappear. Should the young, healthy, unattached man die for the
greater good of saving five lives? This ethical problem, commonly used in
philosophical discussions, is designed to make us consider the effect of one
human sacrifice for the greater good. These utilitarian discussions have
been occurring for centuries, and other than choosing one life over another,
there have not been any real viable answers, until now. The recent advancements in a procedure called bioprinting may make this organ transplant hypothetical moot.
Bioprinting refers to the creation of cartilage, bone, skin, prosthetics, and
even living organs using a three-dimensional printing device.1 Bioprinting
is currently used to create prosthetics and training devices for surgeons, but
is quickly growing into a source for organs to be used in transplants.2 Although this amazing technology could solve the transplant problem described above, it also raises numerous ethical questions that could lead to
legal bans.3 The future of bioprinting will depend on how the technology is
regulated in upcoming years. History illustrates that regulation is slow to
catch up to technology and that will be a major problem for the survival of
bioprinting. This comment will discuss the history of bioprinting and its
1. Meghan McCaffrey, The Stuff of Innovation – 3D Bioprinting and FDA’s Possible Reorganization, WEIL PRODUCT LIABILITY MONITOR (Sept. 10, 2013), http://product-liability.weil.com/news/thestuff-of-innovation-3d-bioprinting-and-fdas-possible-reorganization/.
2. Lyndsey Gilpin, New 3D Bioprinter to Reproduce Human Organs, Changes the Face of
Healthcare: The Inside Story, TECH REPUBLIC, http://www.techrepublic.com/article/new-3d-bioprinterto-reproduce-human-organs/ (last visited Dec. 17, 2014).
3. John Graber, Report Predicts Possible Ban on Bioprinting 2016, 3D PRINTER WORLD (Feb.
14, 2014), http://www.3dprinterworld.com/article/report-predicts-possible-ban-bioprinting-2016.
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expected growth, the ethical implications, necessary regulation, and the
burden on the Federal Food and Drug Administration to adapt and change
with this new technology.
BACKGROUND: BIOPRINTING EXPLAINED AND THE CHALLENGES TO THE
FDA
Over the past few decades, printing has evolved from two-dimensional
printing to an “additive process in which successive layers of material are
distributed to form three-dimensional (3D) shapes.”4 Currently, the most
common uses of 3D printers are to enable rapid prototyping and manufacturing and to produce personalized products in the home.5 Threedimensional printing is also being used in science and education for the
purpose of producing replicas of rare artifacts and models of complex molecules and protein interactions.6
Charles W. Hugh was the first person to describe 3D printing.7 His
method of 3D printing described the layering of thin materials that could be
cured with an ultraviolet light to form a solid 3D structure.8 This layering
process was later used to create “sacrificial resin molds for the formation of
3D scaffolds from biological materials.”9 These 3D scaffolds could be used
for transplantation with or without seeded cells.10 This led to the use of 3D
bioprinting as a form of tissue engineering.11
In bioprinting, plastic and other materials used to create structures with
3D printing are replaced with sensitive, living biological materials.12 The
biological materials are precisely layered with spacial control of the placement of functional components to fabricate 3D functional living human
constructs with biological and mechanical properties suitable for clinical
restoration of tissue and organ function.13 Organ bioprinting is based on
stem cells which serve as the initial material for the bio-ink.14 Stem cells
can serve as the building material for any of the body’s tissues.15 The pa4. Sean V Murphy, Anthony Atala, 3D Bioprinting of Tissues and Organs, 32 NATURE
BIOTECHNOLOGY
773,
773,(2014),
available
at
http://www.nature.com/nbt/journal/v32/n8/full/nbt.2958.html.
5. Id
6. Id.
7. Id.
8. Murphy, supra note 4.
9. Id.
10. Id.
11. Id.
12. Id.
13. Murphy, supra note 4.
14. World’s first 3D-Bioprinted Transplant-Ready Organ to be Unveiled in Early 2015, RT (Nov.
4, 2014 at 7:55 PM), http://rt.com/news/202175-3d-bioprinted-organ-transplant/.
15. Id.
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tient’s cells are aggregated in layers according to a preset digital organ design to form “spheroids” onto hydrogel.16 Once the gel dissolves, the
“printed organ is placed in to a special bio reactor where it matures.”17
Once the organ matures, it is ready to be implanted into the patient. Since
the bioprinted organ is made out of the patients’ own cells, the patients’
body should not reject the organ.
Although there has not been a human transplant of a solid bioprinted organ to date, surgeons have successfully implanted hollow tissues into patients including skin, cartilage and muscles.18 There have also been successful transplants of bladders and urethras into young patients.19 The
world’s first 3D human liver was printed in 2013 and used solely for research purposes.20 Despite the fact that many did not expect bioprinted
organs to be transplant ready for many years, Russia has announced that its
first transplant ready organ, a thyroid, will be released in 2015.21 Russian
Scientists plan to begin their experiment on the thyroid, with further work
on a functional printed kidney scheduled for 2018.22
In order for bioprinting to be used for the creation of viable transplant
organs, it is crucial that the United States Food and Drug Administration
(hereinafter “the FDA”) adjust its approach to the regulation of new medical technology. Technology grows much faster than the pace at which the
FDA regulates. The FDA must take on a more flexible and responsive approach to the regulation of bioprinting technology in order for bioprinting
to revolutionize the healthcare industry.
Although bioprinting has the potential to save many human lives through
the production of living human organs, without proper regulation it can
cause serious harm to both individuals and society as a whole. Bioprinting
is a unique hybrid of technology and biology which makes it a difficult area
to regulate and oversee.23 Bioprinting does not fit within a traditional FDA
category of “device” or “biologic” and that will require the FDA to rethink

16. Id.
17. Id.
ECONOMIST
(Mar.
8,
2014),
18. Printing
a
Bit
of
Me,
THE
http://www.economist.com/news/technology-quarterly/21598322-bioprinting-building-living-tissue-3dprinter-becoming-new-business.
19. Id.
20. Susan Scutti, First 3D Printed Liver Is Mini But Mighty: Could Transplantable Human Organs Eventually Be Bioprinted?, MEDICAL DAILY (Nov. 11, 2013, 4:00 PM),
http://www.medicaldaily.com/first-3d-printed-liver-mini-mighty-could-transplantable-human-organseventually-be-bioprinted-262565.
21. World’s First 3D-Bioprinted Transplant-Ready Organ to be Unveiled in Early 2015, supra
note 14.
22. Id.
23. McCaffrey, supra note 1.
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its regulation process.24 The FDA took note of this challenge when they
decided to form a “Program Alignment Group” tasked to identify and develop “plans to modify FDA’s functions, processes, and possibly its structure in order to address these matters”.25 The FDA is attempting to modify
their approach to regulation because technology has transformed the devices and drugs being produced today. Their past approach was built around
distinguishing products and devices into separate categories, but these categories are now intertwined with one another making their current regulation
process less effective.26
Although it is clear that this reorganization is necessary, what does it
mean for a technology, such as bioprinting, that is in dire need of regulation
now? It means that the FDA must make this reorganization effective and
do so quickly. A major change in the structure and formation of a government agency’s function can be difficult. It can take many years to break up
a government agency’s existing divisions to adopt new programs. Based on
the FDA’s history, it does not adapt to change quickly if at all.27 In 2002,
the FDA announced a reorganization that would merge the FDA’s drug
center with its biologics center.28 Due to internal resistance to the change,
this merger was largely rolled back two years later.29 Not only does the
FDA face the challenge of reorganizing its regulation methods, it must also
overcome the internal resistance it will face in order to allow new technology such as bioprinting to reach its potential as a health care tool.
There are “currently no government regulations on bioprinting,
bioprinted products or the machines.”30 The FDA has only addressed the
regulation of 3D printed medical devices that do not involve living biologic
materials.31 In recent years, it has become common practice to use 3D
printers to produce customized devices such as hearing aids, dental implants, and surgical instruments.32 Although these 3D printed medical devices have become common, the FDA has yet to create custom regulations

24. Id.
25. Scott Gottlieb, Did FDA Just Announce A Major Reorganization?, FORBES (Sept. 8, 2013,
6:27
PM),
http://www.forbes.com/sites/scottgottlieb/2013/09/08/did-fda-just-announce-a-majorreorganization/ .
26. Id.
27. Id.
28. Id.
29. Id.
30. Meghan Neal, 3D Bioprinters Could Make Enhanced, Electricity-Generating ‘Superorgans’,
MOTHERBOARD (June 13, 2014, 1:15 PM), http://motherboard.vice.com/read/3d-bioprinters-couldmake-enhanced-electricity-generating-superorgans.
31. How should FDA treat 3-D printing?, THE ADVISORY BOARD COMPANY (Sept. 5, 2013),
http://www.advisory.com/daily-briefing/2013/09/05/how-should-fda-treat-3-d-printing.
32. Id.
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for such products.33 The FDA currently assesses “3D printed medical devices and conventionally made products under the same guidelines, despite
the different manufacturing methods involved.”34 The FDA is just now
beginning to consider different methods for regulating 3D printed devices
and have yet to officially implement new procedures. It is vital that the
FDA take a more proactive approach to regulating the use of bioprinters.
Since bioprinters combine human cells with 3D printing technology, leaving regulation as it is and only tweaking it once the technology is commonly used would likely result in a dangerous outcome.
FDA regulation is necessary because bioprinting raises many ethical
questions that involve the well-being of patients and society as a whole.
There are questions that need to be heavily discussed and answered before
bioprinting of living organs can become a reality. One of the most alarming
questions regards the possibility that bioprinting could lead to “dystopian
immortality in individuals that can afford to have organs repaired or replaced as they wear out.”35 Although attainable immortality in itself may
seem like an overwhelming thought, what is more concerning is the effect
this could have on society. It is most likely that money would decide who
receives a new organ and who does not, which translates into money determining who lives and who dies.36 The cost of functional organs produced
from a bioprinter will only be available to those financially capable of paying for such personalized treatments.37 This will continue to expand the
access divide between the rich and the poor.
Regulation is necessary to control the purpose of bioprinting. Another
issue to be regulated is the possibility that bioprinting could become related
to performance enhancement in professional sports.38 Athletes will have
the capability to use bioprinting as a tool to repair injured tissues or muscles
or even replace natural muscles with synthetic ones which could unnaturally advance human capabilities.39 This could also lead to the use of
bioprinting for cosmetic purposes. Individuals could design their own nose,
ear, or chin as opposed to trusting the plastic surgeon to construct one out
of their existing body parts. Although this may not seem extreme, where
does it end? If there are no restrictions on the use of the body part or the

33. Id.
34. Id.
35. C. Waldo, Bioprinting (Sept. 25, 2012), http://ethicsof3dprinting.weebly.com/bioprinting.html.
36. Id.
37. Richard Adhikari, Bioprinting, Part 2 – The Ethical Conundrum, TECHNEWSWORLD (Mar. 27,
2014), http://www.technewsworld.com/story/80205.html.
38. Waldo, supra note 35.
39. Id.
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amount created, it is plausible that bioprinting could lead to the construction
of a synthetic human.
Another issue that is likely to result from the bioprinting of organs is the
illegal buying and selling of synthetic organs. Just as there is currently a
black market for human organs, a bioprinted black organ market may result
from the advancement of bioprinting.40 The possibility that individuals
will bioprint organs to make a profit is potentially more dangerous than the
current black market that distributes human organs. Bioprinted organs are
designed and manipulated by a person and then produced by a machine.
There are many more opportunities for error when the organ is being constructed by man and machine than there are when dealing with a human
organ.
ANALYSIS: THE SOLUTION
Although the bioprinting of human organs has not yet been used in human transplants, the issues that must be dealt with when bioprinting is
commonly used are readily apparent. The FDA needs to alter its regulation
approach and begin putting regulations in place now that will guide the
mainstream use of bioprinting rather than waiting until the damage has already been done. The FDA should: (1) develop a detailed plan regarding
how bioprinted organs will be distributed; (2) develop guidelines for determining the eligibility for the allocation of bioprinted organs and tissue; and
(3) determine who will control and monitor the production of human organs.
(1)
Developing a detailed plan regarding how bioprinted organs will
be distributed
The FDA currently regulates human cells or tissues intended for implantation, transplantation, infusion, or transfer into a human recipient, while
The Health Resources and Services Administration (hereinafter “the
HRSA”) oversees the donation and transplantation of vascular organs, such
as hearts, livers, and kidneys.41 The HRSA governs the entire organ donor
process from placing a patient on the waiting list, to matching the patient to
an available organ, to the transplant surgery. Bioprinting technology will
drastically change the process of events for patients in need of an organ and
this will create the need for a new process in the acquisition of a new organ.
40. Id.
41. Tissue
and
Tissue
Product
Questions
and
Answers,
FDA
http://www.fda.gov/BiologicsBloodVaccines/TissueTissueProducts/QuestionsaboutTissues/ucm101559.
htm (last updated Dec. 16, 2014).
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Patients will no longer have to go through the process of being put on a
waiting list, waiting to see if a person who is a match for their specific
transplant dies, going through the transplant surgery, and then waiting to
see if their body accepts or rejects the organ. Although there has yet to be
determined an exact process regarding the patient experience with
bioprinting, it is likely that a doctor will remove cells from the patient and
have those cells used in the production of the necessary organ. Once the
organ has been produced, the doctor will remove the defective organ and
replace it with the bioprinted organ. The bioprinting process revolves
around the doctor and the bioprinter. There is no longer a third party involved, nor is there a risk that the patient’s body will reject the organ.
Since bioprinting is centered on the bioprinter itself, which is a device, it
would be more efficient to have the FDA regulate the organ donor process
as opposed to the HRSA. The FDA already regulates human tissues, and
medical devices. Bioprinting combines a medical device and human cells
and tissues to create the organ to be transplanted. Therefore, it seems most
reasonable for the FDA to maintain the utmost control over the safety of the
transplants and the distribution of the organs.
The method of distribution will determine whether the ethical issue of
“dystopian immortality” truly becomes a reality.42 In establishing a distribution plan for bioprinted organs, it is crucial that the FDA find a middle
ground between the economic requirements of this technology and those in
need of bioprinted organs. The FDA must prevent bioprinting from becoming a luxury for the wealthy. It must be integrated into the health care system in order to become available to individuals of all economic classes.
The FDA should take an approach similar to the current system in which
patients receive organs according to their position on a list. The main difference exists in recognizing that patients are no longer waiting for a match,
but are waiting for a custom creation of an organ made from their own
cells. It may be effective to separate patients into two groups; those in imminent need of an organ and those that can survive without an immediate
transplant. This separation would mirror how hospitals separate patients, in
that those in need of critical care are in the intensive care unit while patients
with less serious injuries or illnesses are not in a specialized unit. This separation would allow the appropriate attention to each patient depending on
their condition, absent regard to their economic status. Patients would not
be able to buy their way into a bioprinted organ because their treatment
would be based on their specific condition. Although the cost of the
bioprinted organ itself may have an effect on who is able to receive it, in42. Waldo, supra note 35.
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surance companies and their regulations regarding bioprinting would deal
with the issue.
(2)
Developing guidelines for determining the eligibility for allocation
of bioprinted organs and tissue
Determining who is and is not eligible for donor organs has always been
a controversial issue. Based on the number of patients in need of a donor
organ and the few organs that become available, eligibility is determined by
a number of psychosocial factors, including age, mental health, and intelligence.43 Allocation decisions have been made by donor programs, hospital
administrators and even physicians.44 This method has contributed greatly
to the accusations of bias allocation and discriminatory allocation.45 This
method would likely be just as inconsistent when dealing with bioprinted
organs.
As suggested by many medical professors and professionals, government
entities may “have the strongest claim to authority to make organ allocation
decisions.”46 Although this solution does not guarantee complete fairness,
by setting out allocation guidelines prior to the mainstreaming of bioprinted
organs, there will be infrastructure for assuring that this technology is being
used in the proper situations.
Currently, one of the largest issues regarding organ allocation is that patients with disabilities are being discriminated against. Although this issue
may exist when bioprinting is used for organ transplant, a larger concern is
that bioprinting will be used for cosmetic or advancement purposes. There
must be limits set on what type of replacement or treatment bioprinting will
be used for in order to avoid the unnatural advancement of human capabilities.47 The most effective way to do this is for the FDA to begin setting
those limitations now.
There are two sides to the creation of enhanced organs, also referred to as
“superorgans.”48 The first is the idea of creating organs that have the capabilities to fight off disease or contribute to the health of the human body.
The possibility of engineering artificial organs to perform specific, useful
functions, such as treating disease is already being discussed by scientists.49
In fact, a 3D printed artificial pancreas that can regulate glucose levels in
43. Joel Frader, Re-evaluating the Recipient Criteria for Organ Transplants, 41 PEDIATRIC
ANNALS 135, 135 (Apr. 2012), available at http://www.healio.com
44. Id.
45. Id.
46. Id.
47. Waldo, supra note 35.
48. Neal, supra note 30.
49. Id.
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diabetic patients is being developed at the University of Iowa’s Advanced
Manufacturing Technology Group.50 Scientists are thinking as extreme as
bioprinted organs that can generate electricity in the human body in order to
power electronic implants like pacemakers without the need for batteries.51
These functions seem reasonable in that they intend to contribute to human
health.
The second side of the creation of “superorgans” is the idea that body
parts can be created to allow for performance or cosmetic enhancements.
There has been a battle in the professional sports industry for years against
the use of performing enhancement drugs, such as steroids. Bioprinting
technology could potentially be used for performance enhancement purposes and could easily exceed the capabilities of any existing performance enhancing drug. Bioprinting would allow the creation of new muscles with
capabilities that surpass those of natural human muscles even with drug
enhancements. Not only could this be a problem for professional sports,
but it could be an issue for law enforcement. If individual citizens were
able to acquire superhuman muscles, traditional police powers may not
have the same control over them, thereby creating a threat to the safety of
others.
The FDA should limit the use of bioprinting to the replacement of organs
and tissue necessary for the survival of patients during the first few years of
its use. Once the number of individuals in need of a bioprinted organ is
under control, the FDA should expand its eligibility requirements to include
patients seeking a bioprinted transplant for the purpose of improving human
health. The FDA should have strict regulations in place to prevent the use
of bioprinters for muscle or organ enhancement for the sole purpose of improving physical performance.
(3)
Determining who will control and monitor the production of human
organs
One of the greatest problems regarding bioprinting is the factor of control
over the production of organs. Control is necessary to prevent the creation
of unauthorized “superorgans,” a bioprinted organ black market, and to
ensure a safe transplant process. The FDA’s regulations regarding the control over the production of bioprinted organs is what allows them to enforce
the other regulations discussed above.
The FDA should suggest the establishment of an agency that will oversee
bioprinting production. This agency will be responsible for the enforce50. Id.
51. Id.
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ment of regulations regarding allocation of bioprinted organs, the order in
which organs are distributed, consultation with insurance companies to establish a fair process for affording bioprinted organs, and ultimately have
control over each functioning bioprinter.
Bioprinters, like any printer, function through a software program. In order to be aware of what organs have been printed, the patients they have
been printed for, and where they have been printed, the agency should create a software used by every bioprinter. This software will allow the agency access to regulate the use of the bioprinters without having physical control of the bioprinting process. The agency would require that each
bioprinter manufacturer install its software on each machine in order for the
machine to be approved by the FDA. The agency would then be able to
review how each bioprinter is used and on which patients. The software
would require the input of each patient’s personal information and the reason the organ is being created for the patient. There would then be a follow-up process to ensure that the patient actually was in medical need of
the bioprinted organ and did in fact receive the organ. This process would
prevent facilities with access to bioprinters from abusing the technology.
By having remote access to every function of the bioprinters, the government will be able to effectively regulate the use of this new technology.
CONCLUSION
There is a need for immediate government regulation of bioprinting. The
FDA has a habit of waiting for the technology to become mainstream prior
to issuing regulation. This method of regulation is insufficient with regards
to new, advanced technologies, such as bioprinting. It is important to remember that although bioprinting is the use of a printer to create a body
part, the product is a living organ or tissue that will be implanted into the
human body. The FDA must adapt to changing technology and begin developing regulation now. It is vital that the FDA considers how these
bioprinted organs will be distributed, what conditions will make an individual eligible for bioprinting, and how to control the production and distribution of bioprinted organs. Bioprinting has the potential to change how we
look at organ transplants, but in order for it to be a successful method, the
FDA must be proactive in regulating the technology.

